CompletedPhase 4

Efficacy and Safety of Nateglinide Treatment in Renal Transplant Recipients

Norway15 participantsStarted 2002-11

Plain-language summary

The objective of the present study is to evaluate both the efficacy and safet of nateglinide in renal transplanta recipients with posttransplant diabetes mellitus or impaired glucose tolerance. Primarily will the change in glucose tolerance and acute insuline responce be addressed.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Reduced glucose tolerance (fasting glucose \< 6.1 mmol/L AND 2 hour glucose between 6.7 and 9.9 mmol/L) or posttransplant diabetes mellitus (fasting glucose \> 6.1 mmol/L OR 2 hour glucose between \>= 10.0 mmol/L) * Stable patients fgollowing renal transplantation, less than 25% variation in serum creatinine last week and serum creatinine \< 200 micromol/L Exclusion Criteria: * Patients with indulin dependent diabetes mellitus before or after transplantation * Planned change in daily prednisolone dose during the study period * Haemoglobin \< 8g/dL

What they're measuring

Glucose tolerance

Insuline release

Trial details

NCT IDNCT00319189

SponsorUniversity of Oslo School of Pharmacy

Sponsor typeOTHER

Study typeINTERVENTIONAL

View on ClinicalTrials.gov More Renal Transplant Recipients trials